SPRAVATO - Johnson & Johnson
Jan 21, 2025 · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO ® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours 1
Johnson & Johnson pivotal study of seltorexant shows …
Titusville, New Jersey (May 29, 2024) – Johnson & Johnson announced today positive topline results from the pivotal Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms ...
FDA approves standalone use of J&J’s ketamine-derived depression ...
Jan 22, 2025 · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...
FDA approves first-of-its-kind nasal spray for severe depression
Jan 22, 2025 · Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...
Johnson & Johnson ketamine-derived nasal spray gets FDA …
Jan 22, 2025 · On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...
Depression | J&J - Johnson & Johnson
Jan 24, 2022 · Live better with depression. Explore Johnson & Johnson's research, treatments & patient stories on depression.
J&J shares data on would-be blockbuster antidepressant
4 days ago · Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial keeps that hope alive.
FDA approves Johnson & Johnson’s nasal spray for depression …
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The ...
FDA Approves Johnson & Johnson's Treatment As First
Jan 21, 2025 · FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials.
J&J’s Spravato Makes Headway in Tough Depression Space With …
Jan 22, 2025 · With an FDA nod on Tuesday, Johnson & Johnson ’s esketamine nasal spray Spravato became the industry’s first monotherapy approved for use in adults with major depressive disorder. The approval gives J&J a boost in a space that has been difficult to crack for biopharma, marked by a series of setbacks in the last year or so.